Publications of R. Hohlfeld
All genres
Journal Article (119)
2007
Journal Article
68 (13), pp. 1076 - 1077 (2007)
NMO-IgG in the diagnosis of neuromyelitis optica. Neurology
Journal Article
5, pp. 2774 - 2783 (2007)
Revised diagnostic criteria for neuromyelitis optica-incorporation of NMO-IgG status. Nature Clinical Practise Neurology
Journal Article
130, pp. 2789 - 2799 (2007)
Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain
Journal Article
78, pp. 1200 - 1208 (2007)
FTY720 (Fingolimod) als neue Therapiemöglichkeit der Multiplen Sklerose. Der Nervenarzt
Journal Article
64, pp. 1331 - 1333 (2007)
Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Archives of Neurology
Journal Article
190 (1-2), pp. 72 - 79 (2007)
CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. Journal of Neuroimmunology
Journal Article
68 (Suppl. 3), p. S1 - S1 (2007)
Neurodegeneration, neuroprotection, glial cells, and myelin in multiple sclerosis. Neurology
Journal Article
204 (10), pp. 2363 - 2372 (2007)
Neurofascin as a novel target for autoantibody-mediated axonal injury. Journal of Experimental Medicine
Journal Article
4 (4), e133, pp. 0669 - 0674 (2007)
Antibody to aquaporin 4 in the diagnosis of neuomyelitis optica. PLoS Medicine
Journal Article
4 (4), pp. 647 - 653 (2007)
Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2006
Journal Article
33 (4), pp. 462 - 476 (2006)
The role of neurotrophins in muscle under physiological and pathological conditions. Muscle & Nerve
Journal Article
131 (1-2), pp. 31 - 34 (2006)
Monoclonal antibodies improve therapy of relapsing multiple sclerosis. Molecular basis and clinical results of anti-VLA4 (natalizumab) therapy. Deutsche Medizinische Wochenschrift
Journal Article
6, pp. 663, 666, 670 - 664, 668 (2006)
Pregnancy and immunomodulatory therapy in multiple sclerosis patients. Nervenarzt
Journal Article
27, pp. S1 - S7 (2006)
The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis. Neurological Sciences
Journal Article
129, pp. 200 - 211 (2006)
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain
Journal Article
22 (4), pp. 183 - 185 (2006)
Biomarkers in multiple sclerosis. Disease Markers
Journal Article
60 (4), p. 487 - 487 (2006)
B lineage cells in inflammatory central nervous system - Reply. Annals of Neurology
Journal Article
59 (6), pp. 880 - 892 (2006)
B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation. Annals of Neurology
Journal Article
103 (32), pp. 12057 - 12062 (2006)
Reconstitution of paired T cell receptor α- and β-chains from microdissected single cells of human inflammatory tissues. Proceedings of the National Academy of Sciences of the United States of America
Journal Article
10, pp. 1235 - 1245 (2006)
Revision of McDonald's new diagnostic criteria for multiple sclerosis. Nervenarzt 2005
Journal Article
252 (8), pp. 968 - 971 (2005)
Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response. Journal of Neurology
Journal Article
4 (9), pp. 567 - 575 (2005)
Glatiramer acetate in multiple sclerosis: Update on potential mechanisms of action. Lancet Neurology
Journal Article
1, pp. 34 - 44 (2005)
Drug insight: Using monoclonal antibodies to treat multiple sclerosis. Nature Clinical Practice Neurology
Journal Article
201 (2), pp. 195 - 200 (2005)
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. Journal of Experimental Medicine
Journal Article
175 (4), pp. 2301 - 2308 (2005)
Expression and function of glial cell line-derived neurotrophic factor (GDNF) family ligands and their receptors on human immune cells. Journal of Immunology
Journal Article
26, pp. 373 - 380 (2005)
Immunobiology of muscle: Advances in understanding an immunological microenvironment. Trends in Immunology
Journal Article
233 (1-2), pp. 109 - 112 (2005)
Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy. Journal of the Neurological Sciences 2004
Journal Article
10, pp. 139 - 144 (2004)
Interferon β-1a in relapsing multiple sclerosis: Four-year extension of the European IFNβ-1a Dose Comparison Study. Multiple Sclerosis Journal
Journal Article
152 (1-2), pp. 168 - 175 (2004)
Antigen recognition properties of a V gamma LW delta 2-T-cell receptor from a rare variant of polymyositis. Journal of Neuroimmunology
Journal Article
16 (6), pp. 799 - 809 (2004)
Distinct responses of monocytes to Toll-like receptor ligands and inflammatory cytokines. International Immunology
Journal Article
10, pp. 16 - 22 (2004)
Immunologic factors in primary progressive multiple sclerosis. Multiple Sclerosis
Journal Article
101 (Suppl. Suppl. 2), pp. 14599 - 14606 (2004)
Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines. Proceedings of the National Academy of Sciences of the United States of America
Journal Article
75 (10), pp. 1022 - 1026 (2004)
Cannabinoids in multiple sclerosis. Opportunity or threat? Nervenarzt
Journal Article
127, pp. 1822 - 1830 (2004)
Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain
Journal Article
101 (8), pp. 2428 - 2433 (2004)
Multiple sclerosis: Brain-infiltrating CD8(+) T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proceedings of the National Academy of Sciences of the United States of America
Journal Article
127, pp. 1370 - 1378 (2004)
Multiple sclerosis: Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2003
Journal Article
74, pp. 1364 - 1370 (2003)
Neuroscience for Neurologists: Molecular pathogenesis of neuroinflammation. Journal of Neurology, Neurosurgery and Psychiatry
Journal Article
362 (9397), p. 1763 - 1763 (2003)
Diagnostic criteria for polymyositis and dermatomyositis - Reply. Lancet
Journal Article
362 (9388), pp. 971 - 982 (2003)
Polymyositis and dermatomyositis. Lancet
Journal Article
163 (4), pp. 1215 - 1226 (2003)
T-cell-mediated autoimmunity - Novel techniques to characterize autoreactive T-cell receptors. American Journal of Pathology
Journal Article
126, pp. 2 - 4 (2003)
Hunting (auto)immune T cells in neuroimmunological diseases. Brain
Journal Article
10, pp. 103 - 105 (2003)
The prospects for neuroprotection in MS. International MS Journal
Journal Article
23, pp. 121 - 131 (2003)
Basic principles of immunotherapy for neurologic diseases. Seminars in Neurology
Journal Article
10 (1), pp. 2 - 4 (2003)
Neurotrophic factors protect myelin from attack. International MS Journal
Journal Article
53 (3), pp. 292 - 304 (2003)
Neurotrophic cross-talk between the nervous and immune systems: Implications for neurological diseases. Annals of Neurology
Journal Article
74, p. 282 - 282 (2003)
Anti-titin antibodies are not associatd with a specific thymoma histology. Journal of Neurology, Neurosurgery and Psychiatry
Journal Article
349 (2), pp. 185 - 186 (2003)
Molecular mimicry in multiple sclerosis. New England Journal of Medicine
Journal Article
126, pp. 176 - 185 (2003)
The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: Implications for myoblast transplnatation and gene therapy. Brain 2002
Journal Article
59 (10), pp. 1507 - 1517 (2002)
A randomised, double-blind, dose-comparison study of weekly interferon ß-1a in relapsing MS. Neurology
Journal Article
123 (1-2), pp. 188 - 192 (2002)
Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. Journal of Neuroimmunology